Arrowhead Pharmaceuticals (ARWR) News Today $19.56 +0.54 (+2.84%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period FDA Accepts Arrowhead Pharmaceuticals' Drug Application for Genetic Disease TreatmentJanuary 17 at 7:51 PM | marketwatch.comArrowhead says FDA accepts NDA for investigational plozasiranJanuary 17 at 7:51 PM | markets.businessinsider.comFDA accepts Arrowhead's NDA for plozasiranJanuary 17 at 7:51 PM | msn.comArrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia SyndromeJanuary 17 at 5:03 PM | businesswire.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives $43.33 Average Target Price from BrokeragesJanuary 14, 2025 | americanbankingnews.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Consensus Rating of "Moderate Buy" from AnalystsArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) has received an average rating of "Moderate Buy" from the ten analysts that are presently covering the firm, Marketbeat reports. Four investment analysts have rated the stock with a hold recommendation and six have issued a buy recommJanuary 11, 2025 | marketbeat.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Up 3.2% - Here's What HappenedArrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Up 3.2% - Here's WhyJanuary 8, 2025 | marketbeat.comInsider Selling: Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CFO Sells 27,167 Shares of StockJanuary 8, 2025 | insidertrades.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CFO Kenneth Allen Myszkowski Sells 27,167 SharesArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) CFO Kenneth Allen Myszkowski sold 27,167 shares of the business's stock in a transaction on Monday, January 6th. The stock was sold at an average price of $19.83, for a total value of $538,721.61. Following the transaction, the chief financial officer now owns 473,433 shares of the company's stock, valued at $9,388,176.39. This trade represents a 5.43 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.January 7, 2025 | marketbeat.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) COO Sells $578,426.88 in StockArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) COO Patrick O'brien sold 29,184 shares of the company's stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $19.82, for a total transaction of $578,426.88. Following the completion of the sale, the chief operating officer now directly owns 535,201 shares of the company's stock, valued at $10,607,683.82. The trade was a 5.17 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.January 7, 2025 | marketbeat.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Insider James C. Hamilton Sells 32,729 SharesArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) insider James C. Hamilton sold 32,729 shares of the firm's stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $19.82, for a total transaction of $648,688.78. Following the completion of the sale, the insider now owns 272,122 shares of the company's stock, valued at $5,393,458.04. This trade represents a 10.74 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.January 7, 2025 | marketbeat.comInsider Selling: Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Sells 11,520 Shares of StockJanuary 7, 2025 | insidertrades.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Sells $219,456.00 in StockArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) CEO Christopher Richard Anzalone sold 11,520 shares of the firm's stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $19.05, for a total value of $219,456.00. Following the transaction, the chief executive officer now owns 3,764,252 shares of the company's stock, valued at $71,709,000.60. This trade represents a 0.31 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.January 6, 2025 | marketbeat.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Down 2.5% - Should You Sell?Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Down 2.5% - Here's What HappenedJanuary 6, 2025 | marketbeat.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by JPMorgan Chase & Co.JPMorgan Chase & Co. reduced its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 7.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,148,405 shares of the biotechnolJanuary 6, 2025 | marketbeat.comWhat is B. Riley's Estimate for ARWR FY2025 Earnings?Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Equities researchers at B. Riley lifted their FY2025 earnings estimates for Arrowhead Pharmaceuticals in a research report issued to clients and investors on Thursday, January 2nd. B. Riley analyst M. Mamtani now forecasts that the bioJanuary 6, 2025 | marketbeat.comArrowhead Pharmaceuticals: Strong Growth Potential Backed by siRNA Therapeutics and Financial StabilityJanuary 3, 2025 | markets.businessinsider.comPrincipal Financial Group Inc. Lowers Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Principal Financial Group Inc. trimmed its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 31.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 290,994 shares ofJanuary 2, 2025 | marketbeat.comAdeoye Y. Olukotun Sells 2,850 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) StockArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) Director Adeoye Y. Olukotun sold 2,850 shares of the stock in a transaction on Friday, December 27th. The stock was sold at an average price of $20.00, for a total value of $57,000.00. Following the completion of the transaction, the director now owns 36,740 shares in the company, valued at approximately $734,800. This represents a 7.20 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.December 30, 2024 | marketbeat.comInsider Selling: Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Sells $246,109.17 in StockDecember 24, 2024 | insidertrades.comArrowhead doses 1st patients in study of ARO-INHBE for obesity treatmentDecember 24, 2024 | markets.businessinsider.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Christopher Richard Anzalone Sells 12,563 SharesArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) CEO Christopher Richard Anzalone sold 12,563 shares of the firm's stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $19.59, for a total value of $246,109.17. Following the completion of the transaction, the chief executive officer now directly owns 3,775,772 shares in the company, valued at $73,967,373.48. This trade represents a 0.33 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.December 23, 2024 | marketbeat.comArrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of ObesityDecember 23, 2024 | businesswire.comGeode Capital Management LLC Acquires 26,171 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Geode Capital Management LLC lifted its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 0.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,964,119December 23, 2024 | marketbeat.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Christopher Richard Anzalone Sells 26,712 SharesDecember 21, 2024 | insidertrades.comInsider Selling: Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Sells 26,712 Shares of StockArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) CEO Christopher Richard Anzalone sold 26,712 shares of the business's stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $21.24, for a total transaction of $567,362.88. Following the transaction, the chief executive officer now directly owns 3,688,335 shares in the company, valued at approximately $78,340,235.40. The trade was a 0.72 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.December 20, 2024 | marketbeat.comIonis FDA approval a positive for Arrowhead, says H.C. WainwrightDecember 20, 2024 | markets.businessinsider.comHC Wainwright Reaffirms Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR)HC Wainwright restated a "buy" rating and set a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Friday.December 20, 2024 | marketbeat.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded at StockNews.comStockNews.com upgraded shares of Arrowhead Pharmaceuticals to a "sell" rating in a research note on Friday.December 20, 2024 | marketbeat.comArrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)December 19, 2024 | businesswire.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Director William D. Waddill Sells 3,748 SharesArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) Director William D. Waddill sold 3,748 shares of Arrowhead Pharmaceuticals stock in a transaction on Monday, December 16th. The shares were sold at an average price of $21.90, for a total transaction of $82,081.20. Following the completion of the transaction, the director now directly owns 44,125 shares in the company, valued at $966,337.50. The trade was a 7.83 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.December 18, 2024 | marketbeat.comLeadership Transition at Arrowhead Pharmaceuticals’ BoardDecember 18, 2024 | markets.businessinsider.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Consensus Recommendation of "Moderate Buy" by BrokeragesShares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) have been given an average rating of "Moderate Buy" by the eleven brokerages that are covering the company, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold rating and seven have assignedDecember 17, 2024 | marketbeat.comQ2 Earnings Estimate for ARWR Issued By B. RileyArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Investment analysts at B. Riley issued their Q2 2025 earnings per share estimates for shares of Arrowhead Pharmaceuticals in a note issued to investors on Thursday, December 12th. B. Riley analyst M. Mamtani anticipates that the biotecDecember 16, 2024 | marketbeat.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Short Interest UpdateArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) was the target of a large increase in short interest in the month of November. As of November 30th, there was short interest totalling 10,070,000 shares, an increase of 6.6% from the November 15th total of 9,450,000 shares. Based on an average daily volume of 1,390,000 shares, the days-to-cover ratio is presently 7.2 days.December 15, 2024 | marketbeat.comState Street Corp Acquires 516,569 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)State Street Corp raised its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 8.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,354,331 sharDecember 15, 2024 | marketbeat.comJane Street Group LLC Has $8.99 Million Stock Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Jane Street Group LLC lowered its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 18.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 463,880 shares of the biotechnology company's stockDecember 14, 2024 | marketbeat.comArrowhead Pharmaceuticals: Positioned for Growth with Strategic Partnerships and siRNA AdvancementsDecember 13, 2024 | markets.businessinsider.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Receives Buy Rating from Chardan CapitalChardan Capital restated a "buy" rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Thursday.December 12, 2024 | marketbeat.comPromising Clinical Trial Results Boost Confidence in Arrowhead Pharmaceuticals, Justifying Buy RatingDecember 12, 2024 | markets.businessinsider.comArrowhead announces interim results from ARO-CFB studyDecember 11, 2024 | markets.businessinsider.comArrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated DiseasesDecember 11, 2024 | finance.yahoo.comShareholders in Arrowhead Pharmaceuticals (NASDAQ:ARWR) have lost 66%, as stock drops 9.3% this past weekDecember 7, 2024 | finance.yahoo.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Purchased by Verition Fund Management LLCVerition Fund Management LLC raised its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 80.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 76,548 shares of the biotechnology company'December 7, 2024 | marketbeat.comWhat is Zacks Small Cap's Estimate for ARWR Q2 Earnings?Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Zacks Small Cap issued their Q2 2025 earnings per share estimates for Arrowhead Pharmaceuticals in a report issued on Tuesday, December 3rd. Zacks Small Cap analyst D. Bautz expects that the biotechnology company will post earnings ofDecember 6, 2024 | marketbeat.comEquities Analysts Set Expectations for ARWR Q1 EarningsArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Stock analysts at HC Wainwright lowered their Q1 2025 earnings per share estimates for Arrowhead Pharmaceuticals in a research note issued to investors on Tuesday, December 3rd. HC Wainwright analyst P. Trucchio now expects that the biDecember 6, 2024 | marketbeat.comFmr LLC Sells 744,664 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Fmr LLC reduced its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 10.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,067,569 shares of the biotechnology company's stock after selDecember 5, 2024 | marketbeat.comErste Asset Management GmbH Buys Shares of 47,000 Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Erste Asset Management GmbH purchased a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 47,000 shares of the biotechnology companyDecember 4, 2024 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Lowers Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 5.9% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,154,250December 4, 2024 | marketbeat.comARWR: License and Collaboration Deal with Sarepta Includes $825 Million Upon Closing…December 4, 2024 | msn.com Get Arrowhead Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter. Email Address ARWR Media Mentions By Week ARWR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARWR News Sentiment▼0.440.44▲Average Medical News Sentiment ARWR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARWR Articles This Week▼56▲ARWR Articles Average Week Get Arrowhead Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Roivant Sciences News Ascendis Pharma A/S News Blueprint Medicines News Revolution Medicines News BridgeBio Pharma News Lantheus News Legend Biotech News Elanco Animal Health News Cytokinetics News Nuvalent News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARWR) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTop Picks for Trump’s Pro-Crypto AmericaThe Crypto ETF Windfall: 27 Experts Tell All (Free) Don't miss your chance to see exactly what crypto's eli...Crypto 101 Media | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Inauguration Shocker: “Move Your Cash Now”Just in the first week after Trump's win, many stocks jumped by double and even triple digits. But now he's...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arrowhead Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arrowhead Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARWR Stock Alerts